7-甲基黄嘌呤在近视防控中的作用：一篇综述
Role of 7-methylxanthine in myopia prevention and control: a mini-review.
作者信息
Lai Lu, Trier Klaus, Cui Dong-Mei
机构信息
Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Futian District, Shenzhen 518040, Guangdong Province, China.
Trier Research Laboratories, Ojenlage Klaus Trier ApS, Hellerup DK-2900, Denmark.
出版信息
Int J Ophthalmol. 2023 Jun 18;16(6):969-976. doi: 10.18240/ijo.2023.06.21. eCollection 2023.
Myopia is becoming increasingly common. By 2050 around 10% of the world's population is expected to be highly myopic (<-5 diopters) and therefore particularly at risk of suffering from sight-threatening complications. Currently used myopia control treatments, such as multifocal soft contact lenses or spectacle lenses, orthokeratology, and atropine eyedrops, either do not completely arrest myopia progression or are associated with significant ocular and possibly systemic side effects. A new candidate for pharmaceutical control of myopia progression and excessive eye elongation, the non-selective adenosine antagonist 7-methylxanthine (7-MX), appears to be non-toxic and effective in reducing myopia progression and axial eye growth in experimental and clinical studies. The latest findings regarding 7-MX for myopia control and evaluate its potential as a supplement to existing treatment options were reviewed.
近视正变得越来越普遍。到2050年，预计全球约10%的人口将高度近视（<-5屈光度），因此特别容易患上威胁视力的并发症。目前使用的近视控制治疗方法，如多焦点软性隐形眼镜或框架眼镜、角膜塑形术和阿托品滴眼液，要么不能完全阻止近视进展，要么会伴有严重的眼部甚至可能的全身副作用。一种用于药物控制近视进展和过度眼轴伸长的新候选药物——非选择性腺苷拮抗剂7-甲基黄嘌呤（7-MX），在实验和临床研究中似乎无毒且能有效减少近视进展和眼轴生长。本文综述了关于7-MX控制近视的最新研究结果，并评估了其作为现有治疗方案补充的潜力。
Zotero 插件